Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Study Design and Initial Baseline Characteristics in Solace-Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease

Matthew M. Heeney, MD, David C. Rees, MD, Mariane de Montalembert, MD PhD, Isaac Odame, MD, R. Clark Brown, MD PhD, Yasser Wali, MD, Thu Thuy Nguyen, Du Lam, MD, Raquel Merino Herranz, Julie Kanter, MD

Blood (2020) 136 (Supplement 1): 22–24.

https://doi.org/10.1182/blood-2020-137081

Published: 2020

Journal Articles

Prevalence, Clinical Characteristics and Outcome of Von Willebrand Disease in Oman

Shamsa Alkaabi, Aala Alzadjali, Mustafa Wasifuddin, Ibrahim Suliman Masoud Alghaithi, MD, Murtadha Al-Khabori, MD, Anil Pathare, MD PhD FCPS, MBBS, Yasser Wali, MD

Blood (2019) 134 (Supplement_1): 4939.

https://doi.org/10.1182/blood-2019-123915

Published: 2019

Journal Articles

The Optimal Cut-Off Level for Hemoglobin A2 to Differentiate between Sickle Cell Disease Genotypes

Fayiz Al Shueili, MD, Murtadha K. Al-Khabori, BSc,MD FRCPC, MSc, Salam Al-Kindi, Yasser Wali, MD, Shoaib Al-Zadjali, PhD

Blood (2018) 132 (Supplement 1): 2391.

https://doi.org/10.1182/blood-2018-99-118697

Published: 2018

Journal Articles

Impact of Treatment Regimen with Moroctocog Alfa (AF-CC) on Bleeding Frequency in Pediatric Aged Subjects with Moderately Severe to Severe Hemophilia A

Mark P. Smith, MD FRACP, FRCPA, Jeremy Rupon, MD, Yasser Wali, MD, Hala Remawi, MD, Joan Korth-Bradley, PharmD, PhD, Lynne Smith, MBA, Pablo Rendo, MD

Blood (2018) 132 (Supplement 1): 1205.

https://doi.org/10.1182/blood-2018-99-111891

Published: 2018

Journal Articles

Avascular Necrosis of the Femoral Head in Sickle Cell Disease in Egypt and Oman: A Cross Sectional Study

Mohsen Saleh Elalfy, MD, Iman Fadhli, Shaimaa Mohammad, Aida Ali, Naema Shibli, Farah Kindi, Sultan Almaskari, Yasser Wali, MD

Blood (2018) 132 (Supplement 1): 4921.

https://doi.org/10.1182/blood-2018-99-116683

Published: 2018

Journal Articles

Liver Enzymes Changes and Safety Profile of Deferasirox Iron Chelator in Omani Children with Thalassemia Major

Surekha Tony Mevada, MD, Abdaluziz Sulieman AlDhuli, A.Hakim Al-Rawas, MD, Murtadha K. Al-Khabori, BSc, MD FRCPC, Hanan Nazir, MD, Mathew Zachariah, MD, Prof. Yasser Wali, MD FRCPCH, (UK)

Blood (2014) 124 (21): 4903.

https://doi.org/10.1182/blood.V124.21.4903.4903

Published: 2014

Journal Articles

Delivering a Hemophilic Newborn with No Intracranial Hemorrhage: Is Caesarian Section the Answer?

Hanan Nazir, MD, Tuqa Allawati, Ismail Elbeshlawi, Murtadha K. Al-Khabori, MD MSc, FRCPC, Sara Alkindi, Wafa Alriyami, Prof. Yasser Wali, MD FRCPCH, (UK)

Blood (2014) 124 (21): 5060.

https://doi.org/10.1182/blood.V124.21.5060.5060

Published: 2014

Journal Articles

Comparison Of Two Combination Iron Chelation Regimens, Deferiprone and Deferasirox Versus Deferiprone and Deferoxamine, In Pediatric Patients With β-Thalassemia Major

Mohsen Saleh Elalfy, Yasser Wali, MD, FRCPCH, (UK), S Tony, Ahmed Samir, Amira Adly

Blood (2013) 122 (21): 559.

https://doi.org/10.1182/blood.V122.21.559.559

Published: 2013

Journal Articles

Outcome of Early Introduction of Hypertransfusion/Chelation Program in Children with Thalassemia Intermedia

Yasser Wali, MD, FRCPCH, (UK), A. Hakim Al-Rawas, MD, Shoaib Al Zadjali, M Sc, Murtadha K. Al-Khabori, MD, MSc, FRCPC, Wafa Bashir, MD, Mathew Zachariah, MD, Taimoora Sulaiman, MD, Surekha Tony, MD

Blood (2012) 120 (21): 3260.

https://doi.org/10.1182/blood.V120.21.3260.3260

Published: 2012

Journal Articles

Dose Optimization of Deferasirox in Chelation Naïve Children with Thalassemia Major

Surekha Tony, MD, Murtadha K. Al-Khabori, MD, FRCPC, Ashraf Abdullah Saad, MBBS, Shahina Daar, MD, PhD, Mathew Zachariah, MD, Yasser Wali, MD, FRCPCH, (UK)

Blood (2011) 118 (21): 5294.

https://doi.org/10.1182/blood.V118.21.5294.5294

Published: 2011

Journal Articles

T2* MRI in Hypertransfused Children with Thalassemia Intermedia: Serum Ferritin Does Not Reflect the Reality

Surekha Tony, MD, Shahina Daar, MD, PhD, Shoaib Al Zadjali, MSc, Murtadha K. Al-Khabori, MD, FRCPC, Mohammed El Shinawy, MD, Yasser Wali, MD, FRCPCH, (UK)

Blood (2011) 118 (21): 5304.

https://doi.org/10.1182/blood.V118.21.5304.5304

Published: 2011

Journal Articles

Optimizing Hydroxyurea Use in Children with Sickle Cell Disease: Least Tolerated Dose Is Effective

Sharef Waadallah Sharef, MD, Maya Al-Hajri, MD, Ismail Beshlawi, MBChB, MM Ped, Amer Qais Al-Shahrabally, FABP, FIBP, MBChB, Yasser Wali, MD, FRCPCH, (UK)

Blood (2011) 118 (21): 4851.

https://doi.org/10.1182/blood.V118.21.4851.4851

Published: 2011

Journal Articles

EARLY Detection of Cardiac and Hepatic Iron Overload by T2* Magnetic Resonance in Very Young Patients with Thalassemia Major in Oman

Surekha Tony, MD, Shahina Daar, MD, Mathew Zachariah, MD, Azza Hinai, MD, Idris Al-Jumah, MD, Salaam Alkindi, MBBCh, MSc, FRCP, Yasser Wali, MD, FRCPCH, (UK)

Blood (2010) 116 (21): 4262.

https://doi.org/10.1182/blood.V116.21.4262.4262

Published: 2010

NARROW

Study Design and Initial Baseline Characteristics in Solace-Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease

Prevalence, Clinical Characteristics and Outcome of Von Willebrand Disease in Oman

The Optimal Cut-Off Level for Hemoglobin A2 to Differentiate between Sickle Cell Disease Genotypes

Impact of Treatment Regimen with Moroctocog Alfa (AF-CC) on Bleeding Frequency in Pediatric Aged Subjects with Moderately Severe to Severe Hemophilia A

Avascular Necrosis of the Femoral Head in Sickle Cell Disease in Egypt and Oman: A Cross Sectional Study

Liver Enzymes Changes and Safety Profile of Deferasirox Iron Chelator in Omani Children with Thalassemia Major

Delivering a Hemophilic Newborn with No Intracranial Hemorrhage: Is Caesarian Section the Answer?

Comparison Of Two Combination Iron Chelation Regimens, Deferiprone and Deferasirox Versus Deferiprone and Deferoxamine, In Pediatric Patients With β-Thalassemia Major

Outcome of Early Introduction of Hypertransfusion/Chelation Program in Children with Thalassemia Intermedia

Dose Optimization of Deferasirox in Chelation Naïve Children with Thalassemia Major

T2* MRI in Hypertransfused Children with Thalassemia Intermedia: Serum Ferritin Does Not Reflect the Reality

Optimizing Hydroxyurea Use in Children with Sickle Cell Disease: Least Tolerated Dose Is Effective

EARLY Detection of Cardiac and Hepatic Iron Overload by T2* Magnetic Resonance in Very Young Patients with Thalassemia Major in Oman

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only